Akèy › Karsinòm selil skuamèz tèt ak kou
Etid klinik pou Karsinòm selil skuamèz tèt ak kou ap rekrite nan Etazini
179 etid pou Karsinòm selil skuamèz tèt ak kou ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Houston, TX47 etid
- Los Angeles, CA42 etid
- Boston, MA40 etid
- New York City, NY39 etid
- Nashville, TN39 etid
- St. Louis, MO28 etid
- Philadelphia, PA26 etid
- Arlington, VA26 etid
- Chicago, IL25 etid
- Atlanta, GA23 etid
- New Haven, CT22 etid
- San Antonio, TX22 etid
- Pittsburgh, PA22 etid
- Dallas, TX20 etid
- Queens, NY20 etid
- Portland, OR19 etid
- Columbus, OH19 etid
- Cleveland, OH18 etid
- Durham, NC17 etid
- Orlando, FL16 etid
- Baldwin Park, CA16 etid
- Miami, FL15 etid
- Tampa, FL15 etid
- Grand Rapids, MI15 etid
- Detroit, MI15 etid
- Baltimore, MD15 etid
- Edison, NJ15 etid
- Charleston, SC14 etid
- San Diego, CA14 etid
- Cincinnati, OH14 etid
- Oklahoma City, OK13 etid
- Santa Monica, CA13 etid
- Milwaukee, WI13 etid
- Omaha, NE13 etid
- Jacksonville, FL12 etid
- Louisville, KY12 etid
- Richmond, VA12 etid
- Cedar Rapids, IA12 etid
- Washington, DC11 etid
- Salt Lake City, UT11 etid
Pa eta
- Alabama7 etid
- Arizona18 etid
- Arkansas10 etid
- Colorado23 etid
- Connecticut24 etid
- Distrik Columbia9 etid
- Florid54 etid
- Georgia25 etid
- Idaho4 etid
- Illinois29 etid
- Indiana13 etid
- Iowa14 etid
- Kalifòni72 etid
- Kansas9 etid
- Kentucky17 etid
- Lwizyàn6 etid
- Maryland18 etid
- Massachusetts42 etid
- Michigan35 etid
- Minnesota23 etid
- Missouri29 etid
- Montana5 etid
- Nebraska15 etid
- Nevada4 etid
- New Hampshire3 etid
- New Jersey26 etid
- New Mexico3 etid
- New York54 etid
- North Carolina27 etid
- North Dakota6 etid
- Ohio46 etid
- Oklahoma14 etid
- Oregon19 etid
- Pennsylvania41 etid
- Rhode Island7 etid
- South Carolina21 etid
- South Dakota9 etid
- Tennessee43 etid
- Texas69 etid
- Utah21 etid
- Vermont3 etid
- Virginia42 etid
- Washington18 etid
- Wisconsin15 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07085091Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06589804A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07814248177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07189871A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07744126Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07360314A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT05877599A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07276399A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06385080Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06980038BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05136196A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
Ap rekriteFaz 1
Laj 18 a 74 · Tout sèks · Mizajou Sep 25, 2026 · NCT07219212JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Ap rekriteFaz 3
Laj 60 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT04892173A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT07229313Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06047379Intratumoral N17350 in Advanced Solid Tumors
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07339176Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Ap rekriteFaz 2
Laj 18 a 79 · Tout sèks · Mizajou Sep 22, 2026 · NCT04671667Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT05983432Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT06736379A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT07730021Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT05267626Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma
Ap rekriteFaz 2
Laj 18 a 120 · Tout sèks · Mizajou Sep 18, 2026 · NCT06161545A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07109726Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
Ap rekriteFaz 2
Laj 18 a 100 · Tout sèks · Mizajou Sep 15, 2026 · NCT05952934ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT05059444Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.